Tempus expands multi-year oncology RWE collaboration with Gilead Sciences

Reuters04-09 20:31
Tempus expands multi-year oncology RWE collaboration with <a href="https://laohu8.com/S/GILD">Gilead</a> Sciences
  • Tempus AI expanded a multi-year strategic collaboration with Gilead Sciences to support Gilead oncology R&D using real-world evidence.
  • Expanded agreement grants Gilead enterprise-wide access to Tempus Lens platform, including broader oncology datasets.
  • Gilead will also use dedicated Tempus analytical services to support oncology pipeline development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260409128442) on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment